SUBSCRIBE: Print / eNewsletter
Researchers looked at whether time to first distant recurrence of metastatic melanoma was linked to survival outcomes.
These findings highlight the need to raise public awareness of the importance of self-skin examination, and to encourage clinicians to have a lower threshold for undertaking skin examinations in bereaved individuals, according to the researchers.
A 79-year-old white man presented with an ulcerated chest wall lesion developing from an existing mole.
A recent study determined circulating tumor cells were associated with melanoma relapse, suggesting that this form of liquid biopsy could help identify patients who would benefit from adjuvant therapy.
The authors indicated that prospective clinical trials investigating DTIC-based systemic chemotherapies and liver-directed treatments are necessary to validate their findings.
The combination of encorafenib and cetuximab has shown promise in clinical testing for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation.
The Memorial Sloan Kettering Cancer Center expert discussed a study he designed to discover why and how melanoma metastasizes, at the 16th International Congress of the Society for Melanoma Research.
The MD Anderson Cancer Center expert discussed how researchers are using genetic alterations to drive specific therapies at the 16th International Congress of the Society for Melanoma Research.
Poulikos Poulikakos, PhD, discussed combining targeted therapy and immunotherapy for the treatment of patients with melanoma at the 16th International Congress of the Society for Melanoma Research.
Sancy Leachman, MD, PhD, discusses her outreach effort titled “War on Melanoma” at the 16th International Congress of the Society for Melanoma Research.
Domenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
